Clinical Trial Update: Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a recombinant anti-EGFR monoclonal antibody in patients with wild-type RAS and BRAF-mutant metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Recombinant anti-EGFR monoclonal antibody

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN